Open AccessClinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial
Author(s) -
Rong Zhang,
Wangyang Pu,
Shuyun Zhang,
Li Chen,
Weipei Zhu,
Li Xiao,
Xing Chen,
Kai Li
Publication year - 2018
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0191756
Subject(s) - ovarian cancer , retrospective cohort study , medicine , alu element , cancer , oncology , cohort , gastroenterology , pathology , biology , genetics , human genome , gene , genome
CA125 amounts have a large overlap in ovarian cancer and benign diseases. We conducted a retrospective cohort trial to assess the clinical value of circulating cell-free DNA concentration and integrity index for the diagnosis of ovarian cancer. A total of 150 patients were recruited. Plasma samples of 24 ovarian cancer patients, 12 benign ovarian cysts, and 12 healthy controls were assessed. By amplifying short ALU-115 repeat and long ALU-219 fragments, circulating cell-free DNA concentrations and integrity index were measured. Plasma ALU-219 fragment levels and integrity index were significantly higher in the ovarian cancer group compared with the benign disease and healthy control groups (p = 0.023 and p = 0.004, respectively). These findings indicated that plasma ALU-219 levels and integrity may have a clinical value in the early diagnosis of ovarian cancer.